Anastasia M. Kochergina
Anastasia M. Kochergina has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
- Ol'Ga Leonidovna Barbarash
Federal State Budgetary Scientific Institution “Research Institute for Complex Issues of Cardiovascular Diseases”, Academician L.S. Barbarash Boulevard, 6, Kemerovo 650002, Russia
14 shared publications - Victoria N. Karetnikova
Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia
9 shared publications - Nikita Alexandrovich Kochergin
Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia
7 shared publications - Vasily Vasilyevich Kashtalap
Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia
7 shared publications - Alina A. Khorlampenko
Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo
6 shared publications O. L. Barbarash
Research institute for complex issues of cardiovascular diseases; Kemerovo state medical university
4 shared publications
Latest Publications
- Open Access
- 31 July 2024
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 64 (7) , 48-55
Possibilities of Azilsartan Medoxomil for Preparation for Planned Percutaneous Coronary Intervention in Patients With Type 2 Diabetes Mellitus
Aim . To evaluate the efficacy and safety of azilsartan medoxomil for preoperative preparation and improving the long-term prognosis of elective percutaneous coronary intervention (PCI) in patients with ischemic heart disease (IHD), arterial hypertension (AH), and type 2 diabetes mellitus (DM). Material and methods . The study sample included patients with type 2 DM referred for elective PCI who had poor blood pressure (BP) control according to 24-hour BP monitoring (24-BPM) (mean daily systolic BP ≥130 mmHg, mean daily diastolic BP ≥80 mmHg). The data were collected from 2018 through 2020. A total of 75 patients was included and distributed by simple randomization into two groups: group 1 (main, n=37) received azilsartan medoxomil as an antihypertensive drug at a dose of 40 mg/day (previously prescribed angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (ARB) were discontinued); group 2 (control, n=38) continued on their previous antihypertensive therapy. The follow-up period was 6 months. During each of 5 consecutive follow-up visits, the patient was examined, 24-BPM was recorded, and urinary markers of renal dysfunction (glomerular filtration rate, GFR; neutrophil gelatinase-associated lipocalin, NGAL; urine albumin-creatinine ratio, UACR; kidney injury molecule, KIM-1; and interleukin-18, IL-18) were measured. Results . During the azilsartan treatment, GFR decreased by 7.4%, while in the control group, it decreased by 18.9% (pConclusion . This study demonstrated two important facts: the possibility for diagnosing contrast-induced acute kidney injury (CI-AKI) using new, more sensitive markers of kidney damage, which is important for assessing the effectiveness of prevention, and the possibility of using ARBs, in particular azilsartan, for the prevention of CI-AKI in patients with IHD in combination with AH and DM.
- 31 July 2024
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 64 (7) , 48-55
Open AccessPossibilities of Azilsartan Medoxomil for Preparation for Planned Percutaneous Coronary Intervention in Patients With Type 2 Diabetes Mellitus
Aim . To evaluate the efficacy and safety of azilsartan medoxomil for preoperative preparation and improving the long-term prognosis of elective percutaneous coronary intervention (PCI) in patients with ischemic heart disease (IHD), arterial hypertension (AH), and type 2 diabetes mellitus (DM). Material and methods . The study sample included patients with type 2 DM referred for elective PCI who had poor blood pressure (BP) control according to 24-hour BP monitoring (24-BPM) (mean daily systolic BP ≥130 mmHg, mean daily diastolic BP ≥80 mmHg). The data were collected from 2018 through 2020. A total of 75 patients was included and distributed by simple randomization into two groups: group 1 (main, n=37) received azilsartan medoxomil as an antihypertensive drug at a dose of 40 mg/day (previously prescribed angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (ARB) were discontinued); group 2 (control, n=38) continued on their previous antihypertensive therapy. The follow-up period was 6 months. During each of 5 consecutive follow-up visits, the patient was examined, 24-BPM was recorded, and urinary markers of renal dysfunction (glomerular filtration rate, GFR; neutrophil gelatinase-associated lipocalin, NGAL; urine albumin-creatinine ratio, UACR; kidney injury molecule, KIM-1; and interleukin-18, IL-18) were measured. Results . During the azilsartan treatment, GFR decreased by 7.4%, while in the control group, it decreased by 18.9% (pConclusion . This study demonstrated two important facts: the possibility for diagnosing contrast-induced acute kidney injury (CI-AKI) using new, more sensitive markers of kidney damage, which is important for assessing the effectiveness of prevention, and the possibility of using ARBs, in particular azilsartan, for the prevention of CI-AKI in patients with IHD in combination with AH and DM.
- Open Access
- 17 April 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (3) , 5831
Single-pill combination of indapamide and perindopril: potential of practical application
The effectiveness of blood pressure control can be increased with the use of single-pill combinations. When choosing an agent, the evidence of its components should be focused. The selection criteria are not only the direct effects of reducing blood pressure, but also organ protection and the impact on prognosis. Perindopril and indapamide have many years of experience in use in a wide range of patients and are used with the same effectiveness in the treatment of hypertension in young and elderly patients, in normal-weight and obese people, as tools for the primary prevention of myocardial infarction and stroke, and also as a way to prevent recurrent events.The article provides data on the advantages of perindopril and indapamide, the potential of its single-pill combination, the pleiotropic and organ protective properties of this drug. We systematized results of related studies and reflected the main conclusions. Attention is paid to the latest data on the long-term effect of indapamide therapy on the risk of cardiovascular events.
- 17 April 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (3) , 5831
Open AccessSingle-pill combination of indapamide and perindopril: potential of practical application
The effectiveness of blood pressure control can be increased with the use of single-pill combinations. When choosing an agent, the evidence of its components should be focused. The selection criteria are not only the direct effects of reducing blood pressure, but also organ protection and the impact on prognosis. Perindopril and indapamide have many years of experience in use in a wide range of patients and are used with the same effectiveness in the treatment of hypertension in young and elderly patients, in normal-weight and obese people, as tools for the primary prevention of myocardial infarction and stroke, and also as a way to prevent recurrent events.The article provides data on the advantages of perindopril and indapamide, the potential of its single-pill combination, the pleiotropic and organ protective properties of this drug. We systematized results of related studies and reflected the main conclusions. Attention is paid to the latest data on the long-term effect of indapamide therapy on the risk of cardiovascular events.
- Open Access
- 25 December 2023
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 12 (4) , 7-19
TYPE 2 MYOCARDIAL INFARCTION: MODERN DIAGNOSTIC TECHNIQUES AND TREATMENT
HighlightsPatients with type 2 myocardial infarction have a more favorable course of the disease in the long-term postinfarction period compared with patients with type 1 myocardial infarction. We have determined the differences in clinical and anamnestic characteristics of patients with type 1 and type 2 MI. AbstractAim. To determine the prevalence of patients with type 2 myocardial infarction (MI) and their features in clinical practice.Methods. The prospective study involved 204 patients with acute coronary syndrome (ACS). The inclusion criteria were as follows: diagnosed ACS at admission followed by a confirmed MI during the inpatient period according to the Fourth Universal definition of MI. The following parameters were analyzed: anthropometric parameters, clinical and anamnestic characteristics, results of laboratory tests, biochemical markers of myocardial necrosis, results of instrumental diagnostics and coronary angiography. A follow-up telephone survey was carried out a year after ACS, noting the following endpoints: repeated coronary events, death, repeated hospitalizations, adherence to medical recommendations, medication taken by the patient.Results. Type 2 MI was diagnosed in 22 (10.8%) patients. The results of coronary angiography revealed either the absence of coronary artery (CA) stenosis or the presence of stenosis of less than 50% without indications of thrombosis in 16 (72.7%) of those patients. Chronic total occlusion of a non-infarct-related artery was found in 6 (27.3%) patients. Patients with type 2 MI were comparable in age with patients with type 1 MI. The group of patients with type 2 MI included more women (p = 0.029), fewer smokers (p = 0.037) and more cases of atrial fibrillation (AF) (p = 0.003) compared to patients with type 1 MI. The factors that were associated with type 2 MI were as follows: sinus tachycardia in 3 (13.6%) patients, paroxysmal atrial flutter or AF with ventricular tachysystole in 4 patients (18.2%).Conclusion. Patients with type 1 MI presented with a less favorable course of the disease: we noted higher number of recurrent MI and deaths one year after the index event compared with patients with type 2 MI. The group of patients with type 2 MI consisted mostly of women, fewer smokers and patients with dyslipidemia, as well as a more frequent indication of AF compared with patients with type 1 MI.
- 25 December 2023
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 12 (4) , 7-19
Open AccessTYPE 2 MYOCARDIAL INFARCTION: MODERN DIAGNOSTIC TECHNIQUES AND TREATMENT
HighlightsPatients with type 2 myocardial infarction have a more favorable course of the disease in the long-term postinfarction period compared with patients with type 1 myocardial infarction. We have determined the differences in clinical and anamnestic characteristics of patients with type 1 and type 2 MI. AbstractAim. To determine the prevalence of patients with type 2 myocardial infarction (MI) and their features in clinical practice.Methods. The prospective study involved 204 patients with acute coronary syndrome (ACS). The inclusion criteria were as follows: diagnosed ACS at admission followed by a confirmed MI during the inpatient period according to the Fourth Universal definition of MI. The following parameters were analyzed: anthropometric parameters, clinical and anamnestic characteristics, results of laboratory tests, biochemical markers of myocardial necrosis, results of instrumental diagnostics and coronary angiography. A follow-up telephone survey was carried out a year after ACS, noting the following endpoints: repeated coronary events, death, repeated hospitalizations, adherence to medical recommendations, medication taken by the patient.Results. Type 2 MI was diagnosed in 22 (10.8%) patients. The results of coronary angiography revealed either the absence of coronary artery (CA) stenosis or the presence of stenosis of less than 50% without indications of thrombosis in 16 (72.7%) of those patients. Chronic total occlusion of a non-infarct-related artery was found in 6 (27.3%) patients. Patients with type 2 MI were comparable in age with patients with type 1 MI. The group of patients with type 2 MI included more women (p = 0.029), fewer smokers (p = 0.037) and more cases of atrial fibrillation (AF) (p = 0.003) compared to patients with type 1 MI. The factors that were associated with type 2 MI were as follows: sinus tachycardia in 3 (13.6%) patients, paroxysmal atrial flutter or AF with ventricular tachysystole in 4 patients (18.2%).Conclusion. Patients with type 1 MI presented with a less favorable course of the disease: we noted higher number of recurrent MI and deaths one year after the index event compared with patients with type 2 MI. The group of patients with type 2 MI consisted mostly of women, fewer smokers and patients with dyslipidemia, as well as a more frequent indication of AF compared with patients with type 1 MI.
- Open Access
- 7 November 2023
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 19 (5) , 520-527
Efficacy of azilsartan medoxomil in patients with hypertension and stable coronary artery disease in combination with type 2 diabetes
Aim. To study the effect of azilsartan medoxomil (AZL-M) on the 24-hour blood pressure (BP) profile in patients with hypertension (HTN), type 2 diabetes (T2D) and stable coronary artery disease (CAD).Material and methods. A total of 183 patients with CAD in combination with HTN and T2D took part in the study (100 men (54,64%), 83 women (45,36%)). All patients were previously prescribed a statin, antiplatelet therapy, a beta-blocker, and an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB). At baseline, the proportion of people taking ARBs and ACEIs was 30% and 70%, respectively. All study participants were discontinued from a previously prescribed ARBs or ACE inhibitors and were prescribed 6-month AZL-M (Edarbi®) therapy. During this period, according to the study plan, patients visited the medical center to assess the effectiveness and safety of therapy and blood pressure changes.Results. The mean age of the patients was 65,0 years (60-69 years), while the mean body mass index (BMI) — 31,24 kg/m2. The mean age of female participants was higher than the mean age of males: 66,35±6,59 vs 62,72±8,82 years (p=0,002). The mean BMI in women was higher and was 33.08 kg/m2, while in men it was 30,74 kg/m2 (p=0,001). Six-month AZL-M therapy decreased 24-hour BP values. Thus, the time index of systolic blood pressure (SBP) hypertension in the daytime decreased from 63% to 12%, while at night from 70% to 10%, and the time index of diastolic blood pressure (DBP) hypertension in the daytime from 18% to 10%, and at night from 44% to 8%. The main result is confirmation of AZL-M effectiveness in relation to BP control, as well as good drug tolerability. At the visit after 1-month AZL-M therapy, target BP values were recorded in 45,4% of participants, and after six months — the proportion of people with normal 24-hour BP values was 69,9%.Conclusion. Edarbi® therapy in patients with HTN in combination with T2D and stable CAD leads to 24-hour BP normalization. At the same time, the drug has a good safety profile, since the reported adverse events were not related to the drug.
- 7 November 2023
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 19 (5) , 520-527
Open AccessEfficacy of azilsartan medoxomil in patients with hypertension and stable coronary artery disease in combination with type 2 diabetes
Aim. To study the effect of azilsartan medoxomil (AZL-M) on the 24-hour blood pressure (BP) profile in patients with hypertension (HTN), type 2 diabetes (T2D) and stable coronary artery disease (CAD).Material and methods. A total of 183 patients with CAD in combination with HTN and T2D took part in the study (100 men (54,64%), 83 women (45,36%)). All patients were previously prescribed a statin, antiplatelet therapy, a beta-blocker, and an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB). At baseline, the proportion of people taking ARBs and ACEIs was 30% and 70%, respectively. All study participants were discontinued from a previously prescribed ARBs or ACE inhibitors and were prescribed 6-month AZL-M (Edarbi®) therapy. During this period, according to the study plan, patients visited the medical center to assess the effectiveness and safety of therapy and blood pressure changes.Results. The mean age of the patients was 65,0 years (60-69 years), while the mean body mass index (BMI) — 31,24 kg/m2. The mean age of female participants was higher than the mean age of males: 66,35±6,59 vs 62,72±8,82 years (p=0,002). The mean BMI in women was higher and was 33.08 kg/m2, while in men it was 30,74 kg/m2 (p=0,001). Six-month AZL-M therapy decreased 24-hour BP values. Thus, the time index of systolic blood pressure (SBP) hypertension in the daytime decreased from 63% to 12%, while at night from 70% to 10%, and the time index of diastolic blood pressure (DBP) hypertension in the daytime from 18% to 10%, and at night from 44% to 8%. The main result is confirmation of AZL-M effectiveness in relation to BP control, as well as good drug tolerability. At the visit after 1-month AZL-M therapy, target BP values were recorded in 45,4% of participants, and after six months — the proportion of people with normal 24-hour BP values was 69,9%.Conclusion. Edarbi® therapy in patients with HTN in combination with T2D and stable CAD leads to 24-hour BP normalization. At the same time, the drug has a good safety profile, since the reported adverse events were not related to the drug.
- Open Access
- 29 September 2023
- Published by Kemerovo State Medical University in Fundamental and Clinical Medicine
- Vol. 8 (3) , 44-52
Preparation of patients with type 2 diabetes mellitus for elective percutaneous coronary intervention
Aim. To assess the quality of preparation of patients with type 2 diabetes mellitus for elective percutaneous coronary intervention, which is aimed to achieving the target values of the modifiable cardiovascular risk factors.Materials and Methods. We retrospectively analysed 100 electronic medical records of patients with type 2 diabetes mellitus who were admitted for elective percutaneous coronary intervention at Research Institute for Complex Issues of Cardiovascular Diseases from 2021 to 2022. We analysed clinicopathological data, the data from clinical laboratory tests, and pharmacological anamnesis.Results. The average age was 65.19 ± 8.69 years, and the proportion of women was 59%. Smoking history and obesity were reported in 22% and 55% of patients, respectively, with average body mass index of 30.38 [27.66; 34.87] kg/m2. All patients suffered from arterial hypertension, 55% had past medical history of myocardial infarction, and 15% had atrial fibrillation. The duration of type 2 diabetes mellitus was 10 [3; 12] years. Target blood pressure at the admission was achieved in 40% patients. Average total cholesterol and blood glucose were 4.15 [3.50; 5.10] mmol/L and 7.85 [6.15; 11.00] mmol/L, respectively. Beta blockers, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, and statics were received by 90%, 89%, and 97% of patients. Maximum statin dose was registered in 27% patients, combined therapy (statin + ezetimibe) was documented in 4% patients. 14% of patients did not take hypoglycemic drugs. Oral hypoglycemic agents were received in 65% (in most cases biguanides and sulphonylureas, in 7% patients they were combined with insulin). Sodium-dependent glucose cotransporter (SGLT2) inhibitors have been taken by 19% of patients.Conclusion. Patients with type 2 diabetes mellitus recommended for elective percutaneous coronary intervention typically suffer from arterial hypertension and frequently had increased body mass index, total cholesterol, and blood glucose. The prevalence of using antihypertensive drugs, oral hypoglycemic agents, and lipid-lowering drugs should be increased.
- 29 September 2023
- Published by Kemerovo State Medical University in Fundamental and Clinical Medicine
- Vol. 8 (3) , 44-52
Open AccessPreparation of patients with type 2 diabetes mellitus for elective percutaneous coronary intervention
Aim. To assess the quality of preparation of patients with type 2 diabetes mellitus for elective percutaneous coronary intervention, which is aimed to achieving the target values of the modifiable cardiovascular risk factors.Materials and Methods. We retrospectively analysed 100 electronic medical records of patients with type 2 diabetes mellitus who were admitted for elective percutaneous coronary intervention at Research Institute for Complex Issues of Cardiovascular Diseases from 2021 to 2022. We analysed clinicopathological data, the data from clinical laboratory tests, and pharmacological anamnesis.Results. The average age was 65.19 ± 8.69 years, and the proportion of women was 59%. Smoking history and obesity were reported in 22% and 55% of patients, respectively, with average body mass index of 30.38 [27.66; 34.87] kg/m2. All patients suffered from arterial hypertension, 55% had past medical history of myocardial infarction, and 15% had atrial fibrillation. The duration of type 2 diabetes mellitus was 10 [3; 12] years. Target blood pressure at the admission was achieved in 40% patients. Average total cholesterol and blood glucose were 4.15 [3.50; 5.10] mmol/L and 7.85 [6.15; 11.00] mmol/L, respectively. Beta blockers, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, and statics were received by 90%, 89%, and 97% of patients. Maximum statin dose was registered in 27% patients, combined therapy (statin + ezetimibe) was documented in 4% patients. 14% of patients did not take hypoglycemic drugs. Oral hypoglycemic agents were received in 65% (in most cases biguanides and sulphonylureas, in 7% patients they were combined with insulin). Sodium-dependent glucose cotransporter (SGLT2) inhibitors have been taken by 19% of patients.Conclusion. Patients with type 2 diabetes mellitus recommended for elective percutaneous coronary intervention typically suffer from arterial hypertension and frequently had increased body mass index, total cholesterol, and blood glucose. The prevalence of using antihypertensive drugs, oral hypoglycemic agents, and lipid-lowering drugs should be increased.
- Open Access
- 4 January 2023
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 27 (12) , 5137
Role of glycemic control in elective percutaneous coronary interventions in patients with type 2 diabetes
Aim. To assess the association of glycemic control (achievement of an individual target glycated hemoglobin level) with the outcomes of elective percutaneous coronary interventions in patients with type 2 diabetes (T2D).Material and methods.This cohort observational study included 74 patients with a median age of 61 (57; 64) years. There were 49% of men with a previously established T2D, who had indications for elective primary percutaneous coronary intervention (PCI) for stable coronary artery disease. At inclusion in the study and after 1 month, the concentration of fasting blood glucose, glycated hemoglobin (HbA1c), fructosamine, and serum creatinine were determined. Plasma glucose levels were determined using the hexokinase method. HbA1clevel was determined by immunoturbidimetry on a Konelab 30i chemistry analyzer. The concentration of fructosamine was determined by the kinetic colorimetric assay on a Konelab 30i chemistry analyzer. Statistical processing was carried out using the Statistica 10.0 program from StatSoft, Inc. (USA).Results.At the time of enrollment, 31% of participants had not achieved the target glycated hemoglobin level against the background of nonoptimal hypoglycemic therapy in most cases. A total of 18 (25%) following adverse cardiovascular events were registered within 12 months after PCI: 11 (15%) patients developed acute coronary syndrome; among them, 6 (8%) patients had stent restenosis according to coronary angiography, 4 (6%) patients — progression of atherosclerosis, which required repeated PCI with stenting of another vessel, 2 (3%) patients — cerebrovascular accident, and 3 (4%) patients were hospitalized due to de compensated heart failure. According to multivariate logistic regression, only the HbA1clevel was a predictor of adverse outcomes during the year after PCI — a 1% increase in HbA1clevel increased the risk of adverse outcomes by 1,79 times (odds ratio, 1,79, 95% confidence interval, 1,06-3,02, p=0,028). Poor glycemic control 1 month before PCI increased the risk of cardiovascular events by 4,04 times over the next year, while non-target HbA1clevel immediately before PCI increased the risk of adverse outcomes by 4,7 times, and 5 months after PCI, by 7,34 times.Conclusion.The significance of non-target glycated hemoglobin level for adverse outcomes during the year after elective PCI against the background of T2D was established with an increase in the negative effect as long-term (after myocardial revascularization) maintenance of poor glycemic control.
- 4 January 2023
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 27 (12) , 5137
Open AccessRole of glycemic control in elective percutaneous coronary interventions in patients with type 2 diabetes
Aim. To assess the association of glycemic control (achievement of an individual target glycated hemoglobin level) with the outcomes of elective percutaneous coronary interventions in patients with type 2 diabetes (T2D).Material and methods.This cohort observational study included 74 patients with a median age of 61 (57; 64) years. There were 49% of men with a previously established T2D, who had indications for elective primary percutaneous coronary intervention (PCI) for stable coronary artery disease. At inclusion in the study and after 1 month, the concentration of fasting blood glucose, glycated hemoglobin (HbA1c), fructosamine, and serum creatinine were determined. Plasma glucose levels were determined using the hexokinase method. HbA1clevel was determined by immunoturbidimetry on a Konelab 30i chemistry analyzer. The concentration of fructosamine was determined by the kinetic colorimetric assay on a Konelab 30i chemistry analyzer. Statistical processing was carried out using the Statistica 10.0 program from StatSoft, Inc. (USA).Results.At the time of enrollment, 31% of participants had not achieved the target glycated hemoglobin level against the background of nonoptimal hypoglycemic therapy in most cases. A total of 18 (25%) following adverse cardiovascular events were registered within 12 months after PCI: 11 (15%) patients developed acute coronary syndrome; among them, 6 (8%) patients had stent restenosis according to coronary angiography, 4 (6%) patients — progression of atherosclerosis, which required repeated PCI with stenting of another vessel, 2 (3%) patients — cerebrovascular accident, and 3 (4%) patients were hospitalized due to de compensated heart failure. According to multivariate logistic regression, only the HbA1clevel was a predictor of adverse outcomes during the year after PCI — a 1% increase in HbA1clevel increased the risk of adverse outcomes by 1,79 times (odds ratio, 1,79, 95% confidence interval, 1,06-3,02, p=0,028). Poor glycemic control 1 month before PCI increased the risk of cardiovascular events by 4,04 times over the next year, while non-target HbA1clevel immediately before PCI increased the risk of adverse outcomes by 4,7 times, and 5 months after PCI, by 7,34 times.Conclusion.The significance of non-target glycated hemoglobin level for adverse outcomes during the year after elective PCI against the background of T2D was established with an increase in the negative effect as long-term (after myocardial revascularization) maintenance of poor glycemic control.
- Open Access
- 31 December 2022
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 62 (12) , 64-72
Cardiometabolic Effects of Empagliflozin in Patients Undergoing Elective Percutaneous Coronary Intervention for Type 2 Diabetes Mellitus
Aim To evaluate cardiometabolic effects of empagliflozin in patients with ischemic heart disease and type 2 diabetes mellitus (DM) following elective percutaneous coronary intervention (PCI). Materials and methods Patients meeting the inclusion/non-inclusion criteria were randomized into two groups of equal number using simple randomization with successively assigned numbers. Group 1 included 37 patients (18 men and 19 women) who gave their consent for the treatment with empagliflozin 10 mg/day in addition to their previous hypoglycemic therapy. The drug administration started one month prior to the elective PCI and continued for the next 11 months (treatment duration, 12 months). Group 2 (comparison group) consisted of age- and DM duration-matched patients (37 patients; 18 men and 19 women) who continued on their hypoglycemic therapy previously prescribed by endocrinologists during the entire study period. Before the study, 36.11 % patients of the empagliflozin group and 27.03 % of the comparison group had unsatisfactory glycemic control as shown by the level of glycated hemoglobin (HbA1c). Results At 6 and 12 months of the study, fasting glycemia and HbA1c were significantly lower in the empagliflozin treatment group. The groups were comparable by the incidence of adverse outcomes: 8 (22.24 %) patients in the empagliflozin group and 10 (27.04 %) patients in the comparison group (р=0.787). The 12-month empagliflozin treatment reduced total cholesterol (C) by 5.56 % (pConclusion The empagliflozin treatment for 30 days prior to and after elective PCI can enhance the effectiveness of myocardial revascularization due to the demonstrated beneficial cardiometabolic effects.
- 31 December 2022
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 62 (12) , 64-72
Open AccessCardiometabolic Effects of Empagliflozin in Patients Undergoing Elective Percutaneous Coronary Intervention for Type 2 Diabetes Mellitus
Aim To evaluate cardiometabolic effects of empagliflozin in patients with ischemic heart disease and type 2 diabetes mellitus (DM) following elective percutaneous coronary intervention (PCI). Materials and methods Patients meeting the inclusion/non-inclusion criteria were randomized into two groups of equal number using simple randomization with successively assigned numbers. Group 1 included 37 patients (18 men and 19 women) who gave their consent for the treatment with empagliflozin 10 mg/day in addition to their previous hypoglycemic therapy. The drug administration started one month prior to the elective PCI and continued for the next 11 months (treatment duration, 12 months). Group 2 (comparison group) consisted of age- and DM duration-matched patients (37 patients; 18 men and 19 women) who continued on their hypoglycemic therapy previously prescribed by endocrinologists during the entire study period. Before the study, 36.11 % patients of the empagliflozin group and 27.03 % of the comparison group had unsatisfactory glycemic control as shown by the level of glycated hemoglobin (HbA1c). Results At 6 and 12 months of the study, fasting glycemia and HbA1c were significantly lower in the empagliflozin treatment group. The groups were comparable by the incidence of adverse outcomes: 8 (22.24 %) patients in the empagliflozin group and 10 (27.04 %) patients in the comparison group (р=0.787). The 12-month empagliflozin treatment reduced total cholesterol (C) by 5.56 % (pConclusion The empagliflozin treatment for 30 days prior to and after elective PCI can enhance the effectiveness of myocardial revascularization due to the demonstrated beneficial cardiometabolic effects.
- Open Access
- 26 June 2022
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 11 (2) , 184-195
Chronic and acute decompensated heart failure: topical issues
Highlights. The article is a review of current literary data on the problem of acute decompensated heart failure. The review highlights the basic principles of the diagnosis and treatment, as well as the problems of their implementation into clinical practice.Abstract Acute decompensated heart failure (ADHF) is a life-threatening condition that requires an emergency hospitalization for intensive treatment. Moreover, it is the event that worsens the patient's further prognosis. Frequent rehospitalizations for decompensation of heart failure reduce life expectancy and quality, and are also a significant economic problem in practical health care. The increasing number of patients with heart failure leads to the growing number of patients seeking medical help for acute decompensated heart failure. More than half of the patients are re-hospitalized within a year for the same reason. The predicted increase in the prevalence of CHF worldwide makes the management of such patients a global medical and social problem. Patients delay, low compliance and insufficient ambulatory monitoring are the factors that need to be influenced in order to improve the prognosis. The article is a review of literary data on the epidemiology of ADHF, diagnosis, treatment and outpatient observation of patients with acute decompensated heart failure. The problems of compliance, the prospects for modern methods of remote monitoring and the possibilities of new drugs are discussed in the article.
- 26 June 2022
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 11 (2) , 184-195
Open AccessChronic and acute decompensated heart failure: topical issues
Highlights. The article is a review of current literary data on the problem of acute decompensated heart failure. The review highlights the basic principles of the diagnosis and treatment, as well as the problems of their implementation into clinical practice.Abstract Acute decompensated heart failure (ADHF) is a life-threatening condition that requires an emergency hospitalization for intensive treatment. Moreover, it is the event that worsens the patient's further prognosis. Frequent rehospitalizations for decompensation of heart failure reduce life expectancy and quality, and are also a significant economic problem in practical health care. The increasing number of patients with heart failure leads to the growing number of patients seeking medical help for acute decompensated heart failure. More than half of the patients are re-hospitalized within a year for the same reason. The predicted increase in the prevalence of CHF worldwide makes the management of such patients a global medical and social problem. Patients delay, low compliance and insufficient ambulatory monitoring are the factors that need to be influenced in order to improve the prognosis. The article is a review of literary data on the epidemiology of ADHF, diagnosis, treatment and outpatient observation of patients with acute decompensated heart failure. The problems of compliance, the prospects for modern methods of remote monitoring and the possibilities of new drugs are discussed in the article.
- Open Access
- 18 March 2022
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 11 (1) , 124-134
Effects of angiotensin II receptor blockers on the course of the disease in patients with stable ischemic heart disease
Highlights. The review synthesizes the results of clinical studies on the use of sartans. This topic is highly relevant due to the antihypertensive, metabolic and organ-protective effect of sartans, which can positively affect the course of coronary atherosclerosis.Abstract. Angiotensin II receptor blockers (sartans) are widely used to treat cardiovascular diseases. This class of drugs has antihypertensive and metabolic effects and organ-protective capabilities. Currently, sartans are of high interest due to their pleiotropic effect: improved lipid metabolism, antidiabetogenic action, nephroprotection, and, as a result, reduced total cardiovascular risk. The article presents an overview of clinical data on the use of sartans in patients with ischemic heart disease, the mechanisms of organ-protective effects and prospects of using this class of drugs for total cardiovascular risk reduction. The following data sources were used: e-Library, ClinicalTrials.gov, PubMed, trialbulletin.com, smartpatients.com, BioPortfolio.com.
- 18 March 2022
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 11 (1) , 124-134
Open AccessEffects of angiotensin II receptor blockers on the course of the disease in patients with stable ischemic heart disease
Highlights. The review synthesizes the results of clinical studies on the use of sartans. This topic is highly relevant due to the antihypertensive, metabolic and organ-protective effect of sartans, which can positively affect the course of coronary atherosclerosis.Abstract. Angiotensin II receptor blockers (sartans) are widely used to treat cardiovascular diseases. This class of drugs has antihypertensive and metabolic effects and organ-protective capabilities. Currently, sartans are of high interest due to their pleiotropic effect: improved lipid metabolism, antidiabetogenic action, nephroprotection, and, as a result, reduced total cardiovascular risk. The article presents an overview of clinical data on the use of sartans in patients with ischemic heart disease, the mechanisms of organ-protective effects and prospects of using this class of drugs for total cardiovascular risk reduction. The following data sources were used: e-Library, ClinicalTrials.gov, PubMed, trialbulletin.com, smartpatients.com, BioPortfolio.com.
- Open Access
- 28 January 2022
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 21 (1) , 2909
Potential of optical coherence tomography and intravascular ultrasound in the detection of vulnerable plaques in coronary arteries
Intravascular imaging of vulnerable plaques in vivo has great potential for predicting coronary events. Currently, there are several methods of intravascular imaging, which make it possible to verify the components of the plaque and, accordingly, its vulnerability. The most common are virtual-histology intravascular ultrasound and optical coherence tomography. Several studies have shown that these imaging techniques can stratify the risk of adverse cardiovascular events, as well as assess the effectiveness of drug therapy. This article will describe the advantages and disadvantages of intravascular ultrasound and optical coherence tomography in identifying vulnerable coronary lesions.
- 28 January 2022
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 21 (1) , 2909
Open AccessPotential of optical coherence tomography and intravascular ultrasound in the detection of vulnerable plaques in coronary arteries
Intravascular imaging of vulnerable plaques in vivo has great potential for predicting coronary events. Currently, there are several methods of intravascular imaging, which make it possible to verify the components of the plaque and, accordingly, its vulnerability. The most common are virtual-histology intravascular ultrasound and optical coherence tomography. Several studies have shown that these imaging techniques can stratify the risk of adverse cardiovascular events, as well as assess the effectiveness of drug therapy. This article will describe the advantages and disadvantages of intravascular ultrasound and optical coherence tomography in identifying vulnerable coronary lesions.